1. Scrip
  2. >>Business

100 More Jobs Cut At Infinity After AbbVie Inevitably Ends Partnership

 
• By Mandy Jackson

AbbVie unsurprisingly walked away from its partnership with Infinity after disappointing Phase II results for the PI3K inhibitor duvelisib. Another 100 Infinity employees will lose their jobs as the company conserves its cash and amends its clinical trial plan.

Infinity Pharmaceuticals Inc. has cut 100 more jobs in the wake of its disappointing Phase II DYNAMO clinical trial for the PI3K inhibitor duvelisib in indolent non-Hodgkin lymphoma (iNHL) now that the inevitable has happened: AbbVie Inc. exercised its right to end the companies' collaboration to develop the drug.

Cambridge, Massachusetts-based Infinity said it would lay off 58% of its staff in light of what was described as a mutual decision to terminate their 2014 agreement, since the company and AbbVie could not restructure their partnership in a way that benefitted both parties

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Scrip

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Atara Does An About Face As FDA Lifts Ebvallo Hold

 
• By Alaric DeArment

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.